China Officially Charges GSK Executives, Details Bribery Practices
This article was originally published in PharmAsia News
Executive Summary
China’s Ministry of Public Security has made formal bribery charges against UK-based drug maker GlaxoSmithKline and former general manager Mark Reilly and two Chinese executives for bribing non-government agencies and personnel.
You may also be interested in...
Chinese-Language Podcast: 聊聊七月生物制药热门话题
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.